بررسی ارتباط سطح سرمی ویسفاتین با شاخص‌های آنتروپومتریک و میزان وزنگیری دوران بارداری مادر

نوع مقاله : اصیل پژوهشی

نویسندگان

1 کارشناس ارشد مامایی، گروه بهداشت باروری و مامایی، دانشکده علوم پزشکی، دانشگاه تربیت مدرس، تهران، ایران. مربی مامایی، دانشکده علوم پزشکی اسفراین، اسفراین، ایران

2 استادیار گروه مامایی و بهداشت باروری، دانشکده علوم پزشکی، دانشگاه تربیت مدرس، تهران، ایران.

3 کارشناس ارشد مامایی، گروه بهداشت باروری و مامایی، دانشکده علوم پزشکی، دانشگاه تربیت مدرس، تهران، ایران.

چکیده

مقدمه: ویسفاتین یک آدیپوکین­ مترشحه از بافت چربی است که به ‌نظر می­رسد با میزان وزن­گیری در دوران بارداری مرتبط باشد، لذا مطالعه حاضر با هدف بررسی سطح سرمی ویسفاتین در بارداری و ارتباط آن با شاخص­های آنتروپومتریک و وزن­گیری دوران بارداری مادر انجام شد.
روش­کار: این مطالعه کوهورت در بازه زمانی آذر ماه سال 1394 تا شهریور سال 1395 بر روی 56 زن باردار 40-18 ساله در سه ماهه­ اول بارداری که برای مراقبت‌های دوران بارداری به مراکز جامع سلامت پرجمعیت مراجعه کرده بودند، انجام شد. زنان باردار از نظر شاخص توده بدنی قبل از بارداری به دو گروه A (BMI طبیعی) و B (BMI بالاتر از طبیعی) تقسیم­بندی و همگن شدند. سطح سرمی ویسفاتین در هفته‌های 12-6 و 20-15 بارداری به روش ELISA سنجش شد. روش گردآوری اطلاعات شامل: مشاهده، معاینه و مصاحبه بیمار با استفاده از پرسشنامه در سه بخش اطلاعات فردی، تاریخچه مامایی و طبی مادری و متغیرهای جنینی، نتایج آزمایشگاهی بود. تجزیه و تحلیل داده­ها با استفاده از نرم‌افزار آماری SPSS و آزمون­های کای دو نمونه­ای، من‌ویتنی، آزمون رتبه علامت‌دار ویلکاکسون، رگرسیون و آزمون همبستگی رتبه­ای اسپیرمن انجام شد. میزان p کمتر از 05/0 معنی­دار در نظر گرفته شد.
یافته­ها: میانگین ویسفاتین سرمی از سه ماهه اول بارداری به سه ماهه دوم بارداری در هر دو گروه به‌طور معنی­داری افزایش پیدا کرده بود (به‌ترتیب 005/0=pa و 001/0= pbدر گروه Aو B). میانگین سطح سرمی ویسفاتین سه ماهه دوم بارداری گروه B نسبت به گروه A به‌طور معناداری بیشتر بود (04/0=p). میزان وزن­گیری در طی سه ماهه دوم بارداری گروه A به‌طور معناداری در مقایسه با گروه B بیشتر بود (03/0=p). سطح ویسفاتین سه ماهه دوم ارتباط مثبت و معناداری با شاخص توده بدنی سه ماهه سوم بارداری در گروه A داشت (01/0=p، 54/0=r).
نتیجه­گیری: الگوی افزایشی در غلظت ویسفاتین پلاسمای مادر با پیشرفت بارداری در زنان باردار در گروه با شاخص توده بدنی طبیعی ممکن است تابعی از تغییرات افزایشی در بافت چربی احشایی باشد که در افزایش انعطاف­پذیری متابولیسم مادران در بارداری و کاهش بروز بیماری­های متابولیک نقش داشته باشد.

کلیدواژه‌ها

عنوان مقاله [English]

Relationship between Serum visfatin with anthropometric indices and maternal gestational weight gain

نویسندگان [English]

  • Ashraf Saber 1
  • Najmeh Tehranian 2
  • Matin Sadat Esmailzade 3
  • Shiva Pourali Roudbaneh 3
1 M.Sc. in Midwifery, Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Instructor, Department of Midwifery, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran
2 Assistant Professor, Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
3 M.Sc. in Midwifery, Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
چکیده [English]

Introduction: Visfatin is an Adipokine secreted from adipose tissue that seems to be related to weight gain during pregnancy. Therefore, this study was performed with aim to determine the relationship between serum visfatin levels in pregnancy with anthropometric indices and maternal gestational weight gain.
Methods: This cohort study was conducted on 56 pregnant women aged 18-40 years at first trimester of pregnancy who had referred to populous health comprehensive centers for prenatal care from December 2015 to September 2016. Pregnant women were divided in terms of BMI before pregnancy to two groups: A (normal BMI) and B (BMI higher than normal). Serum visfatin level was measured in gestational age of 6-12 and 15-20 weeks by ELISA method. Data collection method included observation, examination and interview with patient using the questionnaire in three parts: personal information, maternal medical and obstetric history, and fetal variables, laboratory results. Data was analyzed by SPSS software and Chi-square, Mann-Whitney, Wilcoxon Signed Rank Test, Regression and Spearman ranking correlation tests. P<0.05 was considered statistically significant.
Results: Mean serum visfatin significantly increased from first to second trimesters in both groups (Pa=0.005, Pb=0.001 in A and B groups, respectively). Mean serum visfatin levels at second trimester was significantly higher in B group than A group (p=0.04). Maternal weight gain during second trimester of pregnancy was significantly higher in A group compared with B group (p=0.03). In group A, second trimester visfatin levels had positive and significant relationship with third trimester BMI (p=0.01, r= 0.54).
Conclusion: An incremental pattern of maternal plasma visfatin concentration with pregnancy progression in pregnant women with normal BMI may be a function of incremental changes in visceral adipose tissue, which contributes to increased flexibility of maternal metabolism in pregnancy and reduced incidence of metabolic diseases.

کلیدواژه‌ها [English]

  • Visfatin
  • Weight gain during pregnancy
  • Anthropometric indices

مراجع

  1. Mazidi Sharafabadi F, Haleh Sadrzadeh Y, Hoseiyni M, Najarzadeh A, Mirzaian S. Relationships between weight gain during pregnancy and weight change one year after delivery compared with pre-pregnancy weight in Yazdi women. Iran J Diabetes Metab 2013; 12(4):335-44. (Persian).
  2. Stein TP, Scholl TO, Schluter MD, Schroeder CM. Plasma leptin influences gestational weight gain and postpartum weight retention. Am J Clin Nutr 1998; 68(6):1236-40.
  3. Cunningham F, Leveno K, Bloom S, Spong CY, Dashe J. Williams obstetrics. New York: McGraw-Hill; 2010. P. 148.
  4. Schubring C, Kiess W, Englaro P, Rascher W, Dotsch J, Hanitsch S, et al. Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and placental weight. J Clin Endocrinol Metab 1997; 82(5):1480-3.  
  5. Kim KH, Kim YJ, Lee S, Oh SW, Lee K, Park Y, et al. Evaluation of plasma leptin levels & BMI as predictor of postpartum weight retention. Indian J Med Res 2008; 128(5):595-600. 
  6. de Assis S, Wang M, Goel S, Foxworth A, Helferich W, Hilakivi-Clarke L. Excessive weight gain during pregnancy increases carcinogen-induced mammary tumorigenesis in Sprague-Dawley and lean and obese Zucker rats. J Nutr 2006; 136(4):998-1004.
  7. Khoshkam F, Taghian F, Jalali Dehkordi K. Effect of eight weeks of supplementation of omega-3 supplementation and TRX training on visfatin and insulin resistance in women with polycystic ovary syndrome. Iran J Obstet Gynecol Infertil 2018; 21(9):58-70. (Persian).
  8. Mashhad Taraqi AS, Tehranian N, Roudbaneh SP, Esmaeilzadeh MS, Kazemnejad A, Aghoozi MF, et al. Visfatin as a predictor for growth of fetus and infant. Turk J Obstet Gynecol 2018; 15(2):80-6.
  9. Saber A, Tehranian N, Pourali RS, Esmailzade MS. Role of visfatin in fertility and reproduction: a review study. J Sabzevar Univ Med Sci 2019; 25(6):829-44. (Persian).
  10. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54(10):2911-6.
  11. Porter B, Babbar S, Ye SQ, Maulik D. The role of nicotinamide phosphoribosyltransferase in pregnancy: a review. Am J Perinatol 2016; 33(14):1327-36.
  12. Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002; 187(4):1051-8.
  13. Morgan SA, Bringolf JB, Seidel ER. Visfatin expression is elevated in normal human pregnancy. Peptides 2008; 29(8):1382-9.
  14. Kendal CE, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor (PBEF/visfatin) gene expression is modulated by NF-κB and AP-1 in human amniotic epithelial cells. Placenta 2007; 28(4):305-14.
  15. Ma Y, Cheng Y, Wang J, Cheng H, Zhou S, Li X. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Diabetes Res Clin Pract 2010; 90(1):60-5.
  16. Luo JX, Liu XH, Zhang L, He GL. The expression of visfatin in placenta in women with gestational diabetes mellitus. Sichuan Da Xue Xue Bao Yi Xue Ban 2011; 42(2):204-7.
  17. Mazaki-Tovi S, Vaisbuch E, Romero R, Kusanovic JP, Chaiworapongsa T, Kim SK, et al. Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. J Matern Fetal Neonatal Med 2010; 23(10):1119-28.
  18. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 Suppl 1):S57-63.
  19. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010; 11(1):11-8.
  20. Diamant M, Lamb HJ, van de Ree MA, Endert EL, Groeneveld Y, Bots ML, et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 2005; 90(3):1495-501.
  21. Bluher M. The distinction of metabolically ‘healthy' from ‘unhealthy' obese individuals. Curr Opin Lipidol 2010; 21(1):38-43.
  22. Kinoshita T, Itoh M. Longitudinal variance of fat mass deposition during pregnancy evaluated by ultrasonography: the ratio of visceral fat to subcutaneous fat in the abdomen. Gynecol Obstet Invest 2006; 61(2):115-8.
  23. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, et al. Maternal visfatin concentration in normal pregnancy. J Perinat Med 2009; 37(3):206-17.
  24. Mazaki-Tovi S, Kasher-Meron M, Hemi R, Haas J, Gat I, Lantsberg D, et al. Chemerin is present in human cord blood and is positively correlated with birthweight. Am J Obstet Gynecol 2012; 207(5):412.e1-10.
  25. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49(8):1909-14.
  26. López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55(10):2871-5.
  27. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56(4):565-70.
  28. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M, et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56(8):1131-4.
  29. Kamińska A, Kopczyńska E, Bieliński M, Borkowska A, Junik R. visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders. Endokrynol Pol 2015; 66(2):108-13.
  30. Nowak J, Kulik-Kupka K, Kowalska J, Zieleń-Zynek I, Hudzik B, Żyła A, et al. Visfatin concentration and anthropometric/biochemical parameters in healthy individuals-preliminary study. In20th European Congress of Endocrinology, Barcelona, Spain; 2018. P. 347.
  31. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91(8):3165-70.
  32. Lijun SU, Sun H, Hua S. Correlation between weight gain during late pregnancy and glycated Albumin, Visfatin level and neonatal body composition in gestational diabetes mellitus patients. J Pract Obstet Gynecol 2017; 33(3):194-7.
  33. Misra VK, Trudeau S, Perni U. Maternal serum lipids during pregnancy and infant birth weight: the influence of prepregnancy BMI. Obesity (Silver Spring) 2011; 19(7):1476-81.
  34. Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000; 1(1):47-56.
  35. Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynecol 2007; 50(4):938-48.
  36. Straughen JK, Trudeau S, Misra VK. Changes in adipose tissue distribution during pregnancy in overweight and obese compared with normal weight women. Nutr Diabetes 2013; 3:e84.
  37. Mastorakos G, Valsamakis G, Papatheodorou DC, Barlas I, Margeli A, Boutsiadis A, et al. The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clin Chem 2007; 53(8):1477-83.
  38. Esplin MS, Fausett MB, Peltier MR, Hamblin S, Silver RM, Branch DW, et al. The use of cDNA microarray to identify differentially expressed labor-associated genes within the human myometrium during labor. Am J Obstet Gynecol 2005; 193(2):404-13. 
  39. Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, Mittal P, et al. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition. J Perinat Med 2008; 36(6):485-96.
  40. Tehranian N, Pahlavan F, Tork TF, Asadi E. The relationship between adipokines and cytokines with postpartum depression: a systematic review. J Urmia Nurs Midwifery Facul 2017; 15(3):230-43. (Persian).
مجله زنان، مامایی و نازایی ایران
دوره 22، شماره 5
مرداد 1398
صفحه 43-51

فایل ها

هم رسانی

ارجاع به این مقاله

آمار